Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1981 Sep;44(9):810–813. doi: 10.1136/jnnp.44.9.810

Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage.

U M Chowdhary, K Sayed
PMCID: PMC491141  PMID: 7031186

Abstract

A comparative controlled clinical trial of epsilon aminocaproic acid (EACA), 36 g/day and tranexamic acid (TEA), 6 g/day, was undertaken to assess their effectiveness in reducing early recurrence of subarachnoid haemorrhage (SAH). Of 90 patients treated with EACA recurrent haemorrhage was seen in 8% of these patients and 7% of the patients developed delayed ischaemic deficit. The total pre-operative mortality in EACA-group was 11%. Of 61 patients treated with TEA, 10% had recurrent haemorrhage and delayed ischaemic deficit occurred in 5% of the patients. The total pre-operative mortality in TEA-group was 11%. No difference was found between the effectiveness and side-effects of these drugs.

Full text

PDF
810

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALKJAERSIG N., FLETCHER A. P., SHERRY S. xi-Aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem. 1959 Apr;234(4):832–837. [PubMed] [Google Scholar]
  2. Ameen A. A., Illingworth R. Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm. J Neurol Neurosurg Psychiatry. 1981 Mar;44(3):220–226. doi: 10.1136/jnnp.44.3.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burchiel K. J., Schmer G. A method for monitoring antifibrinolytic therapy in patients with ruptured intracranial aneurysms. J Neurosurg. 1981 Jan;54(1):12–15. doi: 10.3171/jns.1981.54.1.0012. [DOI] [PubMed] [Google Scholar]
  4. Chowdhary U. M., Carey P. C., Hussein M. M. Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon-aminocaproic acid. Lancet. 1979 Apr 7;1(8119):741–743. doi: 10.1016/s0140-6736(79)91204-2. [DOI] [PubMed] [Google Scholar]
  5. Corkill G. Letter: Epsilon-aminocaproic acid and subarachnoid haemorrhage. Lancet. 1974 Nov 30;2(7892):1319–1319. doi: 10.1016/s0140-6736(74)90171-8. [DOI] [PubMed] [Google Scholar]
  6. Fisher C. M., Roberson G. H., Ojemann R. G. Cerebral vasospasm with ruptured saccular aneurysm--the clinical manifestations. Neurosurgery. 1977 Nov-Dec;1(3):245–248. doi: 10.1227/00006123-197711000-00004. [DOI] [PubMed] [Google Scholar]
  7. Fodstad H., Liliequist B., Schannong M., Thulin C. A. Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surg Neurol. 1978 Jul;10(1):9–15. [PubMed] [Google Scholar]
  8. Gelmers H. J. Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid. Acta Neurochir (Wien) 1980;52(1-2):45–50. doi: 10.1007/BF01400945. [DOI] [PubMed] [Google Scholar]
  9. Hunt W. E., Hess R. M. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg. 1968 Jan;28(1):14–20. doi: 10.3171/jns.1968.28.1.0014. [DOI] [PubMed] [Google Scholar]
  10. Kaste M., Ramsay M. Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke. 1979 Sep-Oct;10(5):519–522. doi: 10.1161/01.str.10.5.519. [DOI] [PubMed] [Google Scholar]
  11. Maurice-Williams R. S., Gordon Y. B., Sykes A. Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding? J Neurol Neurosurg Psychiatry. 1980 Feb;43(2):175–181. doi: 10.1136/jnnp.43.2.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Maurice-Williams R. S. Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms? Br Med J. 1978 Apr 15;1(6118):945–947. doi: 10.1136/bmj.1.6118.945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mullan S., Dawley J. Antifibrinolytic therapy for intracranial aneurysms. J Neurosurg. 1968 Jan;28(1):21–23. doi: 10.3171/jns.1968.28.1.0021. [DOI] [PubMed] [Google Scholar]
  14. Nibbelink D. W., Torner J. C., Henderson W. G. Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke. 1975 Nov-Dec;6(6):622–629. doi: 10.1161/01.str.6.6.622. [DOI] [PubMed] [Google Scholar]
  15. Schisano G. The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage. Surg Neurol. 1978 Oct;10(4):217–222. [PubMed] [Google Scholar]
  16. Sengupta R. P., So S. C., Villarejo-Ortega F. J. Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms. J Neurosurg. 1976 Apr;44(4):479–484. doi: 10.3171/jns.1976.44.4.0479. [DOI] [PubMed] [Google Scholar]
  17. Shucart W. A., Hussain S. K., Cooper P. R. Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial. J Neurosurg. 1980 Jul;53(1):28–31. doi: 10.3171/jns.1980.53.1.0028. [DOI] [PubMed] [Google Scholar]
  18. Smith R. R., Upchurch J. J. Monitoring antifibrinolytic therapy in subarachnoid hemorrhage. J Neurosurg. 1973 Mar;38(3):339–344. doi: 10.3171/jns.1973.38.3.0339. [DOI] [PubMed] [Google Scholar]
  19. Tovi D. The use of antifibrinolytic drugs to prevent early recurrent aneurysmal subarachnoid haemorrhage. Acta Neurol Scand. 1973;49(2):163–175. doi: 10.1111/j.1600-0404.1973.tb01288.x. [DOI] [PubMed] [Google Scholar]
  20. Uttley D., Richardson A. E. Letter: E-aminocaproic acid and subarachnoid haemorrhage. Lancet. 1974 Nov 2;2(7888):1080–1081. doi: 10.1016/s0140-6736(74)92181-3. [DOI] [PubMed] [Google Scholar]
  21. van Rossum J., Wintzen A. R., Endtz L. J., Schoen J. H., de Jonge H. Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. Ann Neurol. 1977 Sep;2(3):238–242. doi: 10.1002/ana.410020310. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES